Cercare il medicinale per il nome

Abilify Discmelt e NMS

Risultato del controllo d'interazione tra il farmaco Abilify Discmelt e la malattia NMS su sicurezza in caso d'uso simultaneo.

Risultato di controllo:

Abilify Discmelt <> NMS

Rilevanza: 23.07.2019 Recensore: P.M. Shkutko, dott., in

Durante il controllo d'interazione, secondo le fonti autorevoli Drugs.com, Rxlist.com, Webmd.com, Medscape.com sono trovate le controindicazioni o gli effetti collaterali che possono danneggiare oppure intensificare l’effetto negativo in caso d'uso del farmaco in presenza di questa malattia concomitante.

Consumatore:

La centrale dopaminergici bloccando gli effetti di agenti neurolettici possono precipitare o aggravare potenzialmente mortale sintomo complesso noto come sindrome neurolettica maligna (NMS). NMS è osservata più frequentemente in caso di elevata potenza, agenti come aloperidolo sono somministrati per via intramuscolare, ma può verificarsi con qualsiasi neurolettici agente per qualsiasi lunghezza di tempo. Le manifestazioni cliniche della SMN includono iperpiressia, rigidità muscolare, alterazione stato mentale, instabilità autonomica (irregolarità del polso e della pressione sanguigna, tachicardia, diaforesi e aritmie cardiache). Ulteriori segni possono includere elevati di creatinfosfochinasi, mioglobinuria, e insufficienza renale acuta. Agenti neurolettici non deve essere somministrato a pazienti con l'NMS e deve essere immediatamente interrotto se attualmente amministrati in tali pazienti. In pazienti con una storia di NMS, introduzione o reintroduzione di agenti neurolettici deve essere considerato con attenzione, in quanto NMS può ripresentarsi.

Fonte

Anderson ES, Powers PS "Neuroleptic malignant syndrome associated with clozapine use." J Clin Psychiatry 52 (1991): 102-4
Sharma R, Trappler B, Ng YK, Leeman CP "Risperidone-induced neutroleptic malignant syndrome." Ann Pharmacother 30 (1996): 775-8
"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical, Raritan, NJ.
Hermesh H, Sirota P, Eviatar J "Recurrent neuroleptic malignant syndrome due to haloperidol and amantadine." Biol Psychiatry 25 (1989): 962-5
Najara JE, Enikeev ID "Risperidone and neuroleptic malignant syndrome: a case report." J Clin Psychiatry 56 (1995): 534-5
Tarsy D "Risperidone and neuroleptic malignant syndrome." JAMA 275 (1996): 446
Levenson JL "Neuroleptic malignant syndrome after the initiation of olanzapine." J Clin Psychopharmacol 19 (1999): 477-8
Dave M "Two cases of risperidone-induced neuroleptic malignant syndrome." Am J Psychiatry 152 (1995): 1233-4
Chong LS, Abbott PM "Neuroleptic malignant syndrome secondary to loxapine." Br J Psychiatry 159 (1991): 572-3
Burkhard PR, Vingerhoets FJG "Olanzapine induced neuroleptic malignant syndrome." Arch Gen Psychiat 56 (1999): 101-2
"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals, East Hanover, NJ.
Nemecek D "Atropism may precipitate neuroleptic malignant syndrome during treatment with clozapine." Am J Psychiatry 150 (1993): 1561
Aisen PS, Lawlor BA "Neuroleptic malignant syndrome induced by low-dose haloperidol." Am J Psychiatry 149 (1992): 844
Nyfort-Hansen K, Alderman CP "Possible neuroleptic malignant syndrome associated with olanzapine." Ann Pharmacother 34 (2000): 667
"Product Information. Loxitane C Oral Concentrate (loxapine)" Watson Laboratories Inc, Corona, CA.
Singer S, Richards C, Boland RJ "Two cases of risperidone-induced neuroleptic malignant syndrome." Am J Psychiatry 152 (1995): 1234
"Product Information. Risperdal (risperidone)." Janssen Pharmaceutica, Titusville, NJ.
"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb, Princeton, NJ.
"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company, Indianapolis, IN.
Levitt AJ, Midha R, Craven JL "Neuroleptic malignant syndrome with intravenous haloperidol." Can J Psychiatry 35 (1990): 789
Ewert AL, Kloek J, Wells B, Phelps S "Neuroleptic malignant syndrome associated with loxapine" J Clin Psychiatry 44 (1983): 37-8
Webster P, Wijeratne C "Risperidone-induced neuroleptic malignant syndrome." Lancet 344 (1994): 1228-9
"Product Information. Orap Tablets (pimozide)." Gate Pharmaceuticals, Sellersville, PA.
"Product Information. Moban (molindone)." Gate Pharmaceuticals, Sellersville, PA.
Kern JL, Cernek PK "Delayed risperidone-induced malignant syndrome." Ann Pharmacother 30 (1996): 300
Ryken TC, Merrell AN "Haloperidol-induced neuroleptic malignant syndrome in a 67-year-old woman with parkinsonism." West J Med 151 (1989): 326-8
Moltz DA, Coeytaux RR "Case report: Possible neuroleptic malignant syndrome associated with olanzapine." J Clin Psychopharmacol 18 (1998): 485-6
Gleason PP, Conigliaro RL "Neuroleptic malignant syndrome with risperidone." Pharmacotherapy 17 (1997): 617-21
Caroff SN "The neuroleptic malignant syndrome." J Clin Psychiatry 41 (1980): 79-83
Raitasuo V, Vataja R, Elomaa E "Risperidone-induced neuroleptic malignant syndrome in young patient." Lancet 344 (1994): 1705
"Product Information. Navane (thiothixene)." Roerig Division, New York, NY.
Campellone JV, Mccluskey LF, Greenspan D "Fatal outcome from neuroleptic malignant syndrome associated with clozapine." Neuropsychiatry Neuropsychol Behav Neurol 8 (1995): 70-3
DasGupta K, Young A "Clozapine-induced neuroleptic malignant syndrome." J Clin Psychiatry 52 (1991): 105-7
Johnson V, Bruxner G "Neuroleptic malignant syndrome associated with olanzapine." Aust N Z J Psychiat 32 (1998): 884-6
Margolese HC, Chouinard G "Olanzapine-induced neuroleptic malignant syndrome with mental retardation." Am J Psychiat 156 (1999): 1115-6
SierraBiddle D, Herran A, DiezAja S, GonzalezMata JM, Vidal E, DiezManrique F, VazquezBarquero JL "Neuroleptic malignant syndrome and olanzapine." J Clin Psychopharmacol 20 (2000): 704-5
Miller DD, Sharafuddin MJ, Kathol RG "A case of clozapine-induced neuroleptic malignant syndrome." J Clin Psychiatry 52 (1991): 99-101
"Product Information. Seroquel (quetiapine)." Zeneca Pharmaceuticals, Wilmington, DE.
"Product Information. Geodon (ziprasidone)." Pfizer US Pharmaceuticals, New York, NY.
Padgett R, Lipman E "Use of neuroleptics after an episode of neuroleptic malignant syndrome" Can J Psychiatry 34 (1989): 323-5